XML 59 R51.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Intangible assets - Additional information (Details) $ in Millions |  | 1 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | --- | ---
Jun. 01, 2022 USD ($) | Jul. 31, 2023 EUR (€) | Oct. 31, 2022 EUR (€) | Jan. 31, 2022 EUR (€) | Oct. 31, 2020 EUR (€) | Jun. 30, 2020 EUR (€) | Apr. 30, 2020 EUR (€) | Jun. 30, 2019 EUR (€) | Jun. 30, 2024 EUR (€) | Jun. 30, 2023 EUR (€) | Dec. 31, 2022 EUR (€) | Dec. 31, 2023 EUR (€) | Jul. 31, 2017 EUR (€)
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets other than goodwill |  |  |  |  |  |  |  |  | € 119,000 | € 903,000 | € 1,556,000 | € 416,000 |
Additional considerations |  |  |  |  |  |  |  |  | 0 | 2,000,000 |  |  |
Financial liabilities |  |  |  |  |  |  |  |  | 35,503,000 | € 40,658,000 | 42,251,000 | 39,893,000 |
2014 Monalizumab (NKG2A) agreement with Novo Nordisk |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets other than goodwill |  |  |  |  |  |  |  |  | 119,000 |  |  | € 416,000 |
IPH5201 (anti-CD39) rights acquired from Orega Biotech |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |  |  |  |  |  |
Additional considerations |  | € 2,000,000 | € 600,000 | € 400,000 |  | € 200,000 | € 2,500,000 | € 7,000,000 |  |  |  |  |
Agreement related to IPH5201 with AstraZeneca |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment received | $ | $ 5 |  |  |  |  |  |  |  |  |  |  |  |
IPH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets other than goodwill |  |  |  |  |  |  |  |  |  |  |  |  | € 40,000,000
Payments for milestone |  |  |  |  | € 1,000,000 |  |  |  |  |  |  |  |
Financial liabilities |  |  |  |  |  |  |  |  | € 0 |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  |  |  | € 41,000,000 |  |

X
- References No definition available. + Details
Name: | ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfIntangibleAssetsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_FinancialLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_IntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents payments for milestone. + References No definition available. + Details
Name: | inpha_PaymentsForMilestone
Namespace Prefix: | inpha_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue From Contracts With Customers, Milestone Payment Received + References No definition available. + Details
Name: | inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived
Namespace Prefix: | inpha_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=inpha_AgreementRelatedToIPH5201WithAstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |